A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Patients with hematologic malignancies
• At least 18 years old
Locations
Other Locations
Israel
Meir Medical Center
RECRUITING
Kfar Saba
Rabin Medical Center
RECRUITING
Petah Tikva
Contact Information
Primary
Adi Zoref Lorenz, MD
adi.zoref.lorenz@cchmc.org
513 6525610
Backup
Noa Rabinowicz, PhD
noa.rabinowicz@clalit.org.il
+972-54-4864564
Time Frame
Start Date: 2021-03-03
Estimated Completion Date: 2030-03-03
Participants
Target number of participants: 300
Treatments
OHI+ patients
Adult patients with hematologic malignancies that have sCD25\>3,900 U/mL and ferritin \>1,000 ng/mL
OHI- patients
Adult patients with hematologic malignancies, with sCD25\>3,900 U/mL and/or ferritin \< 1,000 ng/mL
Related Therapeutic Areas
Sponsors
Collaborators: Rabin Medical Center, Sheba Medical Center, Children's Hospital Medical Center, Cincinnati, Schneider Children's Medical Center, Israel
Leads: Meir Medical Center